“Long-Term Efficacy of Certolizumab Pegol Dosed at 400 Mg Every Two Weeks in Patients With Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S36, https://doi.org/10.25251/skin.3.supp.36.